Literature DB >> 3415714

Influence of moxaverine hydrochloride on membrane curvature and microsieve filterability of red cells after exposure to hyperosmolarity and lactacidosis.

H Schmid-Schönbein1, S Schröder, R Grebe, G Artmann, H Eschweiler, P Teitel.   

Abstract

Using a combination of novel techniques to assess quantitatively the shape and the filterability of red blood cells (RBC) after exposure to stress conditions (400 mosmol/l, lactacidosis, pH 6.8), the effects of 1-benzyl-3-ethyl-6,7-dimethoxy-isoquinoline hydrochloride (moxaverine-HCl, Kollateral) were tested. The shape of freely suspended RBC was quantified using the tangent count procedure. The filterability (microrheological performance) of leukocyte-free RBC suspensions was determined by computer-assisted conductometry using novel precision metal microsieves with uniform pore diameter of 4.2 micron. Moxaverine, when present in doses between 10(-5) und 10(-2) mol/l while the RBC are stressed, restored both the normal discoid red cell configuration and the microrheological performance when tested under low shear stresses. The data show that moxaverine, a papaverine derivative, hitherto considered as a classical vasodilator exerts protective effects on RBC membrane curvature and whole cell microrheological behavior (performance). The protective effects manifest themselves when the RBC's are exposed to abnormal biochemical conditions such as they might occur in poststenotic areas, where hypoxic ischemia is known to lead to a combination of hyperosmolarity and lactacidosis which modify the RBCs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3415714

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  1 in total

1.  Effects of orally administered moxaverine on ocular blood flow in healthy subjects.

Authors:  Doreen Schmidl; Berthold Pemp; Michael Lasta; Agnes Boltz; Semira Kaya; Stefan Palkovits; Franz Prager; Leopold Schmetterer; Gerhard Garhofer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-01       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.